Oncologica®, a trailblazer in the field of precision oncology, stands as a beacon of hope for cancer patients by offering tailored testing services that revolutionize personalized cancer treatment. Founded in 2014, Oncologica® has been committed to leveraging molecular sequencing technologies to expand the horizons of personalized medicine, specifically targeting patients grappling with cancer.
At the core of Oncologica®'s mission lies the provision of precision oncology testing, a groundbreaking service that meticulously matches cancer patients with the most suitable targeted therapies and immunotherapies based on their distinct tumor mutation profiles. This pioneering approach ensures that patients receive treatments tailored to their unique genetic makeup, optimizing the efficacy of interventions and potentially enhancing outcomes.
Beyond its stellar advancements in personalized cancer medicine, Oncologica® also stands as a pivotal player in combating the COVID-19 pandemic. The laboratory extends its expertise to offer COVID-19 testing services and viral sequencing, playing a crucial role in tracking and understanding emerging SARS-CoV-2 variants.
With its inception, Oncologica® swiftly earned recognition as one of the first clinically approved laboratories in Europe to harness the potential of genomic profiling for personalized cancer medicine. This breakthrough facilitated a comprehensive link between specific cancer genetic mutations and the most appropriate targeted therapies, fundamentally reshaping the landscape of cancer treatment.
The organization's commitment to precision oncology doesn't stop there. Oncologica® continues to pioneer and provide a spectrum of services that ensure patients derive maximum benefit from the evolving realm of personalized drugs. Their role at the forefront of precision oncology services is pivotal in enabling patients to access the full potential of tailored medications.
In addition to their clinical services, Oncologica® operates as a Contract Research Organisation (CRO), offering robust support for biomarker and drug development programs. Their proven portfolio, consisting of comprehensive genomic profiling and tumor-based assays, serves as a cornerstone in aiding theranostic programs across all phases of cancer development, from initial discovery to clinical trials.
Moreover, Oncologica® drives innovation through its in-house Research and Development (R&D) initiatives. These programs are dedicated to crafting novel diagnostic and therapeutic strategies, elevating the clinical management of patients grappling with advanced cancer. By capitalizing on the latest scientific and technical developments in cancer genomics, Oncologica® strives to improve treatment decisions and ultimately enhance patient outcomes.
In essence, Oncologica®'s multifaceted approach, combining cutting-edge testing services, pioneering research endeavors, and unwavering dedication to personalized medicine, marks it as a pioneering force in the ongoing quest to redefine cancer treatment and patient care.
